Shapiro, other attorneys general detail proposed $48 billion national opioid settlement | TribLIVE.com
U.S./World

Shapiro, other attorneys general detail proposed $48 billion national opioid settlement

Deb Erdley
1836997_web1_ptr-Shapiro06-081319
Nate Smallwood | Tribune-Review
Pennsylvania Attorney General Josh Shapiro

The nation’s three largest drug distribution companies and two drug companies have agreed to a tentative national settlement of opioid lawsuits valued at $48 billion, including $22 billion in cash and $26 billion in the form of treatment drugs and delivery services, a team of attorneys general announced Monday.

Pennsylvania Attorney General Josh Shapiro joined attorneys general from North Carolina, Tennessee and Texas to announce the tentative deal that would require a buy-in from states and municipalities across the nation struggling with the opioid crisis. The attorneys general said the proposed deal offers the best opportunity to get help to those struggling with addiction as soon as possible.

Some 2,300 counties, states, municipalities and Native American tribes have suits pending against drug distributors and manufacturers. The suit calls them complicit in the opioid epidemic that has led to tens of thousands of deaths a year and a crushing financial burden on those dealing with the cost of treatment.

“We are proud of this solution. We believe it is going to bring a national solution to a national project. We are optimistic we will get other states as well as the cities and counties on board with this deal,” said Texas Attorney General Ken Paxton.

The deal has yet to be approved by the courts and ratified by the states. It followed marathon negotiating sessions with distributors AmerisourceBergen, Cardinal Health and McKesson and drug manufacturers Teva and Johnson & Johnson over the last week, as a federal case involving two Ohio counties appeared poised to go to trial.

That case settled out of court for $260 million Monday.

The pending national settlement would break down as follows:

  • $22.25 billion in cash, including $18 billion from the three distribution companies, $4 billion from Johnson & Johnson and $250 million from Teva.
  • $23 billion in wholesale valued Suboxone — the primary drug used in medicated addiction treatment — from Teva.
  • $2.5 billion in free distribution from three distribution companies.
  • $500 million to establish a national clearinghouse to monitor drug distribution practices.

“Nearly one-third of the cash (will be) paid out in the first three years,” Shapiro said of the plan. “Free medication will begin to be distributed immediately.”

He warned that failure to approve such a settlement could result in the bankruptcy of some of the defendants and years of litigation with awards going out at random and haphazardly to those who get to court first.

Deb Erdley is a Tribune-Review staff writer. You can contact Deb at 724-850-1209, [email protected] or via Twitter .

Categories: News | Pennsylvania | World
TribLIVE commenting policy

You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.